U.S. flag

An official website of the Department of Health & Human Services

AHRQ: Agency for Healthcare Research and Quality

Search AHRQ

For an exact phrase match, enclose search terms in double quotes.

Go to Advanced Search
Go to Basic Search

Results

Total Results: 534 records

Showing results for "aaa".
Users also searched for: falls

  1. Section 5, Appendix 1, Tables 1-5 (pdf file)

    www.qualitymeasures.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-150-section-5-appendix-1-tables-1-5.pdf
    October 22, 2013 - in Children and Adolescents on Antipsychotics Organization (Date) Recommendation Type/Grade AACAP-AAA … Guideline “Careful attention should be given to the increased risk of developing diabetes with the use of AAA … /low quality evidence all AAAs except Ziprasidone, weak recommendation/ consensus based). 1C (all AAA … children and adolescents on AAAs (strong recommendation with high to low evidence depending upon the AAA … Group—Psychopharmacological treatment for very young children: Contexts and guidelines.5 “Use of AAA

  2. Section 5, Appendix 1, Tables 1-5 (pdf file)

    www.innovations.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-150-section-5-appendix-1-tables-1-5.pdf
    October 22, 2013 - in Children and Adolescents on Antipsychotics Organization (Date) Recommendation Type/Grade AACAP-AAA … Guideline “Careful attention should be given to the increased risk of developing diabetes with the use of AAA … /low quality evidence all AAAs except Ziprasidone, weak recommendation/ consensus based). 1C (all AAA … children and adolescents on AAAs (strong recommendation with high to low evidence depending upon the AAA … Group—Psychopharmacological treatment for very young children: Contexts and guidelines.5 “Use of AAA

  3. Section 5, Appendix 1, Tables 1-5 (pdf file)

    www.healthcare411.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-150-section-5-appendix-1-tables-1-5.pdf
    October 22, 2013 - in Children and Adolescents on Antipsychotics Organization (Date) Recommendation Type/Grade AACAP-AAA … Guideline “Careful attention should be given to the increased risk of developing diabetes with the use of AAA … /low quality evidence all AAAs except Ziprasidone, weak recommendation/ consensus based). 1C (all AAA … children and adolescents on AAAs (strong recommendation with high to low evidence depending upon the AAA … Group—Psychopharmacological treatment for very young children: Contexts and guidelines.5 “Use of AAA

  4. Section 5, Appendix 1, Tables 1-5 (pdf file)

    ce.effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/pqmp/measures/chronic/chipra-150-section-5-appendix-1-tables-1-5.pdf
    October 22, 2013 - in Children and Adolescents on Antipsychotics Organization (Date) Recommendation Type/Grade AACAP-AAA … Guideline “Careful attention should be given to the increased risk of developing diabetes with the use of AAA … /low quality evidence all AAAs except Ziprasidone, weak recommendation/ consensus based). 1C (all AAA … children and adolescents on AAAs (strong recommendation with high to low evidence depending upon the AAA … Group—Psychopharmacological treatment for very young children: Contexts and guidelines.5 “Use of AAA

  5. Other Resources | Agency for Healthcare Research and Quality

    www.qualitymeasures.ahrq.gov/pqmp/implementation-qi/toolkit/antipsychotic/other-resources.html
    September 01, 2021 - and Adolescents Guideline (Date) Population Recommendation or Statement Type/Grade AACAP-AAA … children and adolescents. 18 5-18 years “Prior to the initiation of and during treatment with an AAA … /low quality evidence all AAAs except Ziprasidone, weak recommendation/ consensus based). 1C (all AAA … children and adolescents on AAAs (strong recommendation with high to low evidence depending upon the AAA … Group – Psychopharmacological treatment for very young children: contexts and guidelines. 32 “Use of AAA

  6. Other Resources | Agency for Healthcare Research and Quality

    www.talkingquality.ahrq.gov/pqmp/implementation-qi/toolkit/antipsychotic/other-resources.html
    September 01, 2021 - and Adolescents Guideline (Date) Population Recommendation or Statement Type/Grade AACAP-AAA … children and adolescents. 18 5-18 years “Prior to the initiation of and during treatment with an AAA … /low quality evidence all AAAs except Ziprasidone, weak recommendation/ consensus based). 1C (all AAA … children and adolescents on AAAs (strong recommendation with high to low evidence depending upon the AAA … Group – Psychopharmacological treatment for very young children: contexts and guidelines. 32 “Use of AAA

  7. Other Resources | Agency for Healthcare Research and Quality

    www.cahps.ahrq.gov/pqmp/implementation-qi/toolkit/antipsychotic/other-resources.html
    September 01, 2021 - and Adolescents Guideline (Date) Population Recommendation or Statement Type/Grade AACAP-AAA … children and adolescents. 18 5-18 years “Prior to the initiation of and during treatment with an AAA … /low quality evidence all AAAs except Ziprasidone, weak recommendation/ consensus based). 1C (all AAA … children and adolescents on AAAs (strong recommendation with high to low evidence depending upon the AAA … Group – Psychopharmacological treatment for very young children: contexts and guidelines. 32 “Use of AAA

  8. Other Resources | Agency for Healthcare Research and Quality

    www.healthcare411.ahrq.gov/pqmp/implementation-qi/toolkit/antipsychotic/other-resources.html
    September 01, 2021 - and Adolescents Guideline (Date) Population Recommendation or Statement Type/Grade AACAP-AAA … children and adolescents. 18 5-18 years “Prior to the initiation of and during treatment with an AAA … /low quality evidence all AAAs except Ziprasidone, weak recommendation/ consensus based). 1C (all AAA … children and adolescents on AAAs (strong recommendation with high to low evidence depending upon the AAA … Group – Psychopharmacological treatment for very young children: contexts and guidelines. 32 “Use of AAA

  9. Other Resources | Agency for Healthcare Research and Quality

    www.innovations.ahrq.gov/pqmp/implementation-qi/toolkit/antipsychotic/other-resources.html
    September 01, 2021 - and Adolescents Guideline (Date) Population Recommendation or Statement Type/Grade AACAP-AAA … children and adolescents. 18 5-18 years “Prior to the initiation of and during treatment with an AAA … /low quality evidence all AAAs except Ziprasidone, weak recommendation/ consensus based). 1C (all AAA … children and adolescents on AAAs (strong recommendation with high to low evidence depending upon the AAA … Group – Psychopharmacological treatment for very young children: contexts and guidelines. 32 “Use of AAA

  10. Other Resources | Agency for Healthcare Research and Quality

    www.monahrq.ahrq.gov/pqmp/implementation-qi/toolkit/antipsychotic/other-resources.html
    September 01, 2021 - and Adolescents Guideline (Date) Population Recommendation or Statement Type/Grade AACAP-AAA … children and adolescents. 18 5-18 years “Prior to the initiation of and during treatment with an AAA … /low quality evidence all AAAs except Ziprasidone, weak recommendation/ consensus based). 1C (all AAA … children and adolescents on AAAs (strong recommendation with high to low evidence depending upon the AAA … Group – Psychopharmacological treatment for very young children: contexts and guidelines. 32 “Use of AAA

  11. Other Resources | Agency for Healthcare Research and Quality

    ce.effectivehealthcare.ahrq.gov/pqmp/implementation-qi/toolkit/antipsychotic/other-resources.html
    September 01, 2021 - and Adolescents Guideline (Date) Population Recommendation or Statement Type/Grade AACAP-AAA … children and adolescents. 18 5-18 years “Prior to the initiation of and during treatment with an AAA … /low quality evidence all AAAs except Ziprasidone, weak recommendation/ consensus based). 1C (all AAA … children and adolescents on AAAs (strong recommendation with high to low evidence depending upon the AAA … Group – Psychopharmacological treatment for very young children: contexts and guidelines. 32 “Use of AAA

  12. Psn-Pdf (pdf file)

    psnet.ahrq.gov/node/852698/psn-pdf
    August 30, 2023 - A lack of screening was a significant issue identified in the eA process for AAA.1 Based on the eA/ … increased the screening rate to identify early AAA, and decreased the rate of failure to recognize … and follow up diagnosed AAA. … The 2011 eA review for AAA identified 24 patients who died with a diagnosis of ruptured AAA in a KPSC … After implementation of these system improvements, the number and rate of AAA rupture has decreased

  13. The e-Autopsy/e-Biopsy: A Systematic Chart Review to Increase Safety and Diagnostic Accuracy Innovation | PSNet

    psnet.ahrq.gov/innovation/e-autopsye-biopsy-systematic-chart-review-increase-safety-and-diagnostic-accuracy
    April 01, 2005 - A lack of screening was a significant issue identified in the eA process for AAA. 1 Based on the eA … increased the screening rate to identify early AAA, and decreased the rate of failure to recognize and … follow up diagnosed AAA. … This and other system improvements reduced the number and rate of AAA ruptures (average of 1.03/100,000 … The 2011 eA review for AAA identified 24 patients who died with a diagnosis of ruptured AAA in a KPSC

  14. AHRQ QI Rate Comparison v2019, v2020 (pdf file)

    qualityindicators.ahrq.gov/Downloads/Software/V2021/AHRQ_QI_Rate_Comparison_v20120_v2021.pdf
    July 01, 2021 - Rate Stratum B: Absence of Pancreatic Cancer 1.00 25.76 25.76 IQI 11 Abdominal Aortic Aneurysm (AAA … ) Repair Mortality Rate 1.00 34.72 34.72 IQI 11_ OPEN_RUPTURED Abdominal Aortic Aneurysm (AAA) … D Abdominal Aortic Aneurysm (AAA) Repair Mortality Rate Stratum: Open Repair of Unruptured AAA … 1.00 53.42 53.42 IQI 11_ ENDO_RUPTURED Abdominal Aortic Aneurysm (AAA) Repair Mortality Rate … Aortic Aneurysm (AAA) Repair Mortality Rate Stratum: Endovascular Repair of Unruptured AAA 1.00

  15. Evidence Summary: Aspirin Use to Prevent Cancer: Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication | United States Preventive Services Taskforce

    www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary-aspirin-to-prevent-cancer/aspirin-to-prevent-cardiovascular-disease-and-cancer
    April 11, 2016 - , BMD, ETDRS, JPAD, POPADAD, TPT ǁ BMD, TPT ǁ AAA, BMD, JPAD, TPT ǁ , POPADAD AAA, BMD, ETDRS, … AAA = Aspirin for Asymptomatic Atherosclerosis; ABI = ankle–brachial index; BMD = British Male Doctors … , BMD * , HOT, POPADAD, PPP Primary ≥4 y Any 4 49,641 0.98 (0.92–1.05) AAA, BMD * , … POPADAD, WHS Primary ≥4 y Daily 3 9765 0.88 (0.75–1.02) AAA, BMD * , POPADAD … ≥1 y ≤100 mg/d 5 67,787 0.98 (0.93–1.04) AAA, HOT, POPADAD, PPP, WHS Rothwell 2012

  16. Archived: Evidence Summary: Aspirin Use to Prevent Cancer: Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication | United States Preventive Services Taskforce

    www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary-aspirin-to-prevent-cancer/aspirin-to-prevent-cardiovascular-disease-and-cancer-april-2016
    April 11, 2016 - , BMD, ETDRS, JPAD, POPADAD, TPT ǁ BMD, TPT ǁ AAA, BMD, JPAD, TPT ǁ , POPADAD AAA, BMD, ETDRS, … AAA = Aspirin for Asymptomatic Atherosclerosis; ABI = ankle–brachial index; BMD = British Male Doctors … , BMD * , HOT, POPADAD, PPP Primary ≥4 y Any 4 49,641 0.98 (0.92–1.05) AAA, BMD * , … POPADAD, WHS Primary ≥4 y Daily 3 9765 0.88 (0.75–1.02) AAA, BMD * , POPADAD … ≥1 y ≤100 mg/d 5 67,787 0.98 (0.93–1.04) AAA, HOT, POPADAD, PPP, WHS Rothwell 2012

  17. Aspirin for the Prevention of Cancer Incidence and Mortality: Systematic Evidence Reviews for the USPSTF (pdf file)

    www.uspreventiveservicestaskforce.org/home/getfilebytoken/Njxn2r3qtWKdBf2_VhS2Aw
    April 01, 2016 - CRC cases, 240 CRC deaths k = 2; n = 7588; 216 incident CRC cases Primary CVD prevention studies AAA … , BMD, ETDRS, JPAD, POPADAD, TPT�� BMD, TPT�� AAA, BMD, JPAD, TPT��, POPADAD AAA, BMD, ETDRS, HOT, … et al, 1988 (BMD) (54) Belch et al, 2008 (POPADAD) (55) MRC, 1998 (TPT) (52) Fowkes et al, 2010 (AAA … AAA = Aspirin for Asymptomatic Atherosclerosis; ABI = ankle–brachial index; BMD = British Male Doctors … (0.74–0.99) AAA, BMD*, POPADAD (SAPAT) Primary ≥1 y ≤325 mg/d 5 67 787 0.98 (0.93–1.04) AAA, HOT, POPADAD

  18. Healthcare Cost and Utilization Project (HCUP) NASS Notes

    hcup-us.ahrq.gov/db/vars/dxccsr_aaannn/nassnote.jsp
    August 01, 2019 - Clinical Classifications Software Refined (CCSR): ICD-10-CM Diagnosis Classification within Body System AAA … The value of AAA indicates the body system. … Clinical Classifications Software Refined (CCSR): ICD-10-CM Diagnosis Classification within Body System AAA

  19. Evidence Summary: Peripheral Artery Disease and Cardiovascular Disease: Screening and Risk Assessment With the Ankle-Brachial Index | United States Preventive Services Taskforce

    www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/peripheral-artery-disease-in-adults-screening-with-the-ankle-brachial-index
    July 10, 2018 - Mean follow-up was 8.2 years in the AAA trial, which was terminated early because of futility, and 6.7 … The AAA trial recruited men and women from the community aged 50 to 75 years (mean, 62.0 years) with … Of the participants, 55.9% and 71.5% were women in the POPADAD and AAA trials, respectively. … In AAA and POPADAD, 33% and 31% of participants, respectively, were current smokers. … Both the AAA and the POPADAD trials reported bleeding harms associated with use of 100 mg of aspirin

  20. Healthcare Cost and Utilization Project (HCUP) NIS Notes

    hcup-us.ahrq.gov/db/vars/prccsr_aaannn/nisnote.jsp
    September 01, 2008 - Classifications Software Refined (CCSR): ICD-10-PCS Procedure Classification within Clinical Domain aaa … The value of AAA indicates the clinical domain. … Classifications Software Refined (CCSR): ICD-10-PCS Procedure Classification within Clinical Domain aaa
SHARE:
Facebook Twitter Print Facebook Share

Search the AHRQ Archive

Information and reports more than 5 years old may be found in the AHRQ Archive site.

Search Archive

Search Within A Specific AHRQ Site

Click to show only results for the selected site.

hcup-us.ahrq.gov (78)

nhqrnet.ahrq.gov (68)

www.ahrq.gov (64)

qualityindicators.ahrq.gov (43)

www.uspreventiveservicestaskforce.org (42)

ce.effectivehealthcare.ahrq.gov (30)

www.qualitymeasures.ahrq.gov (17)

www.talkingquality.ahrq.gov (16)

www.healthcare411.ahrq.gov (15)

www.innovations.ahrq.gov (15)

www.monahrq.ahrq.gov (15)

psnet.ahrq.gov (14)

www.cahps.ahrq.gov (13)

effectivehealthcare-admin.ahrq.gov (11)

effectivehealthcare.ahrq.gov (11)

pcmh.ahrq.gov (10)

www.cpsi.ahrq.gov (9)

cahps.ahrq.gov (8)

healthcare411.ahrq.gov (8)

monahrq.ahrq.gov (8)

digital.ahrq.gov (7)

pbrn.ahrq.gov (7)

talkingquality.ahrq.gov (7)

ahrqpubs.ahrq.gov (6)

patientregistry.ahrq.gov (6)

teamstepps.ahrq.gov (5)

cds.ahrq.gov (1)